glp 1 and watery diarrhea Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus Understanding GLP-1 side effects

A recent 20-week, phase II trial investigated the effects of subcutaneous administration of semaglutide 2.4 mg on gastric emptying, appetite, and energy intake in patients with obesity

Hyaluronic acid as sodium hyaluronate

Semaglutide and GLP-1 medications mimic hormone receptor agonists known as glucagon-like peptide-1 agonists

Through downregulating monocyte chemoattractant protein-1 expression, semaglutide treatment, an FDA-approved GLP-1 RA medicine targeting Type II diabetes mellitus (T2DM) (Christou et al., 2019), inhibited monocyte migration and infiltration from the circulatory system to inflammatory regions (Pontes-da-Silva et al., 2022)